Type i interferons

Ancient peptides with still under-discovered anti-cancer properties

Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese, Giovanni Vitale

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.

Original languageEnglish
Pages (from-to)412-423
Number of pages12
JournalProtein and Peptide Letters
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Interferons
Cytokines
Peptides
Interferon Type I
Neoplasms
Tumors
Genetic engineering
Cellular radio systems
Signal transduction
Recombinant DNA
Cell growth
Cell Differentiation
Signal Transduction
Chemical activation
Technology
Growth

Keywords

  • Egf-p
  • Farnesyltransferase inhibitors
  • Interferon-alpha
  • Interferon-beta
  • Mtor
  • Pegylated interferons
  • Stats
  • Type i interferons

ASJC Scopus subject areas

  • Biochemistry
  • Structural Biology

Cite this

Type i interferons : Ancient peptides with still under-discovered anti-cancer properties. / Caraglia, Michele; Dicitore, Alessandra; Marra, Monica; Castiglioni, Sara; Persani, Luca; Sperlongano, Pasquale; Tagliaferri, Pierosandro; Abbruzzese, Alberto; Vitale, Giovanni.

In: Protein and Peptide Letters, Vol. 20, No. 4, 04.2013, p. 412-423.

Research output: Contribution to journalArticle

Caraglia, Michele ; Dicitore, Alessandra ; Marra, Monica ; Castiglioni, Sara ; Persani, Luca ; Sperlongano, Pasquale ; Tagliaferri, Pierosandro ; Abbruzzese, Alberto ; Vitale, Giovanni. / Type i interferons : Ancient peptides with still under-discovered anti-cancer properties. In: Protein and Peptide Letters. 2013 ; Vol. 20, No. 4. pp. 412-423.
@article{bc67c9e744504ba5814e5f97c74b085f,
title = "Type i interferons: Ancient peptides with still under-discovered anti-cancer properties",
abstract = "Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.",
keywords = "Egf-p, Farnesyltransferase inhibitors, Interferon-alpha, Interferon-beta, Mtor, Pegylated interferons, Stats, Type i interferons",
author = "Michele Caraglia and Alessandra Dicitore and Monica Marra and Sara Castiglioni and Luca Persani and Pasquale Sperlongano and Pierosandro Tagliaferri and Alberto Abbruzzese and Giovanni Vitale",
year = "2013",
month = "4",
doi = "10.2174/092986613805290372",
language = "English",
volume = "20",
pages = "412--423",
journal = "Protein and Peptide Letters",
issn = "0929-8665",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Type i interferons

T2 - Ancient peptides with still under-discovered anti-cancer properties

AU - Caraglia, Michele

AU - Dicitore, Alessandra

AU - Marra, Monica

AU - Castiglioni, Sara

AU - Persani, Luca

AU - Sperlongano, Pasquale

AU - Tagliaferri, Pierosandro

AU - Abbruzzese, Alberto

AU - Vitale, Giovanni

PY - 2013/4

Y1 - 2013/4

N2 - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.

AB - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.

KW - Egf-p

KW - Farnesyltransferase inhibitors

KW - Interferon-alpha

KW - Interferon-beta

KW - Mtor

KW - Pegylated interferons

KW - Stats

KW - Type i interferons

UR - http://www.scopus.com/inward/record.url?scp=84877959168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877959168&partnerID=8YFLogxK

U2 - 10.2174/092986613805290372

DO - 10.2174/092986613805290372

M3 - Article

VL - 20

SP - 412

EP - 423

JO - Protein and Peptide Letters

JF - Protein and Peptide Letters

SN - 0929-8665

IS - 4

ER -